Search results
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 2 hours agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 3 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 2 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 1 day agoIn addition, immune system irregularities, higher diagnosis rates, increased focus on early...
Beese Fulmer Investment Management Inc. Sells 137 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 14 hours agoBeese Fulmer Investment Management Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.6% during the first quarter, according to the company in its most recent 13F filing with ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 1 day agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 9 hours agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis& ...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 1 day agoEverything you need to know about the art and science of drug naming in five minutes or less,...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 2 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
Short Interest in UCB SA (OTCMKTS:UCBJY) Rises By 152.5%
ETF DAILY NEWS· 7 days agoUCB SA (OTCMKTS:UCBJY – Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 15,400 shares, a growth of 152.5% from ...